REPLIGEN CORP (RGEN) Stock Fundamental Analysis
USA - NASDAQ:RGEN - US7599161095 - Common Stock
147.74 USD
-1.26 (-0.85%)
RGEN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
RGEN had a positive operating cash flow in the past year.
RGEN had positive earnings in 4 of the past 5 years.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
RGEN's Return On Assets of 0.06% is fine compared to the rest of the industry. RGEN outperforms 68.97% of its industry peers.
RGEN's Return On Equity of 0.08% is fine compared to the rest of the industry. RGEN outperforms 70.69% of its industry peers.
RGEN has a Return On Invested Capital (1.05%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for RGEN is significantly below the industry average of 13.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN has a Profit Margin of 0.25%. This is in the better half of the industry: RGEN outperforms 68.97% of its industry peers.
Looking at the Operating Margin, with a value of 6.58%, RGEN is in the better half of the industry, outperforming 62.07% of the companies in the same industry.
RGEN's Operating Margin has declined in the last couple of years.
RGEN has a Gross Margin of 51.59%. This is comparable to the rest of the industry: RGEN outperforms 56.90% of its industry peers.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, RGEN has more shares outstanding
The number of shares outstanding for RGEN has been increased compared to 5 years ago.
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
RGEN has an Altman-Z score of 6.89. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.89, RGEN belongs to the top of the industry, outperforming 87.93% of the companies in the same industry.
The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
RGEN has a Debt to FCF ratio of 5.05. This is in the better half of the industry: RGEN outperforms 70.69% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
RGEN has a Debt to Equity ratio (0.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 6.89 |
ROIC/WACC0.11
WACC9.89%
2.3 Liquidity
RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a better Current ratio (8.36) than 89.66% of its industry peers.
A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
The Quick ratio of RGEN (7.14) is better than 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.17% over the past year.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
RGEN shows a decrease in Revenue. In the last year, the revenue decreased by -8.54%.
Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.53% on average per year.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.90% yearly.
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 89.00, which means the current valuation is very expensive for RGEN.
RGEN's Price/Earnings ratio is in line with the industry average.
RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.56.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 68.81.
The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
The average S&P500 Price/Forward Earnings ratio is at 34.62. RGEN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 89 | ||
| Fwd PE | 68.81 |
4.2 Price Multiples
RGEN's Enterprise Value to EBITDA is on the same level as the industry average.
RGEN's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 78.06 | ||
| EV/EBITDA | 73.64 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as RGEN's earnings are expected to grow with 23.00% in the coming years.
PEG (NY)5.91
PEG (5Y)12.52
EPS Next 2Y20.45%
EPS Next 3Y23%
5. Dividend
5.1 Amount
RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RGEN (11/18/2025, 11:58:57 AM)
147.74
-1.26 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.43%
Inst Owner Change17.02%
Ins Owners0.5%
Ins Owner Change-7.68%
Market Cap8.31B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts80.71
Price Target181.69 (22.98%)
Short Float %6.32%
Short Ratio3.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.06%
PT rev (3m)-1.05%
EPS NQ rev (1m)-11.77%
EPS NQ rev (3m)-10.34%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)-0.64%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 89 | ||
| Fwd PE | 68.81 | ||
| P/S | 11.74 | ||
| P/FCF | 78.06 | ||
| P/OCF | 63.5 | ||
| P/B | 3.99 | ||
| P/tB | 14.46 | ||
| EV/EBITDA | 73.64 |
EPS(TTM)1.66
EY1.12%
EPS(NY)2.15
Fwd EY1.45%
FCF(TTM)1.89
FCFY1.28%
OCF(TTM)2.33
OCFY1.57%
SpS12.58
BVpS37.03
TBVpS10.22
PEG (NY)5.91
PEG (5Y)12.52
Graham Number37.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 6.89 |
F-Score6
WACC9.89%
ROIC/WACC0.11
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year75.45%
EBIT Next 3Y40.62%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 89 and the Price/Book (PB) ratio is 3.99.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 15.05% in the next year.